We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Read MoreHide Full Article
For the quarter ended September 2023, Baxter International (BAX - Free Report) reported revenue of $3.71 billion, down 1.7% over the same period last year. EPS came in at $0.68, compared to $0.82 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.69 billion, representing a surprise of +0.52%. The company delivered an EPS surprise of +3.03%, with the consensus EPS estimate being $0.66.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Sales- Acute Therapies- U.S. $66 million versus the three-analyst average estimate of $59.38 million. The reported number represents a year-over-year change of +24.5%.
Sales- Acute Therapies- International: $122 million versus $112.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.2% change.
Sales- Pharmaceuticals- U.S. $195 million versus the three-analyst average estimate of $184.52 million. The reported number represents a year-over-year change of +12.7%.
Sales- Pharmaceuticals- International: $385 million compared to the $369.56 million average estimate based on three analysts. The reported number represents a change of +9.4% year over year.
Sales- Advanced Surgery- U.S. $139 million versus $147.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1.4% change.
Geographic Sales- International: $1.94 billion compared to the $1.89 billion average estimate based on three analysts. The reported number represents a change of -6.2% year over year.
Sales- Other- U.S. $12 million versus $24.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -57.1% change.
Sales- Acute Therapies: $188 million versus the four-analyst average estimate of $172.03 million. The reported number represents a year-over-year change of +19%.
Sales- Pharmaceuticals: $580 million versus $548.31 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.5% change.
Sales- Front Line Care: $301 million versus $307.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change.
Sales- Other: $17 million compared to the $34.84 million average estimate based on four analysts. The reported number represents a change of -55.3% year over year.
Sales- Advanced Surgery: $255 million versus the four-analyst average estimate of $260.06 million. The reported number represents a year-over-year change of +3.2%.
Shares of Baxter have returned -11.3% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Baxter (BAX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended September 2023, Baxter International (BAX - Free Report) reported revenue of $3.71 billion, down 1.7% over the same period last year. EPS came in at $0.68, compared to $0.82 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $3.69 billion, representing a surprise of +0.52%. The company delivered an EPS surprise of +3.03%, with the consensus EPS estimate being $0.66.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Sales- Acute Therapies- U.S. $66 million versus the three-analyst average estimate of $59.38 million. The reported number represents a year-over-year change of +24.5%.
- Sales- Acute Therapies- International: $122 million versus $112.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.2% change.
- Sales- Pharmaceuticals- U.S. $195 million versus the three-analyst average estimate of $184.52 million. The reported number represents a year-over-year change of +12.7%.
- Sales- Pharmaceuticals- International: $385 million compared to the $369.56 million average estimate based on three analysts. The reported number represents a change of +9.4% year over year.
- Sales- Advanced Surgery- U.S. $139 million versus $147.44 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -1.4% change.
- Geographic Sales- International: $1.94 billion compared to the $1.89 billion average estimate based on three analysts. The reported number represents a change of -6.2% year over year.
- Sales- Other- U.S. $12 million versus $24.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -57.1% change.
- Sales- Acute Therapies: $188 million versus the four-analyst average estimate of $172.03 million. The reported number represents a year-over-year change of +19%.
- Sales- Pharmaceuticals: $580 million versus $548.31 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +10.5% change.
- Sales- Front Line Care: $301 million versus $307.48 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +7.9% change.
- Sales- Other: $17 million compared to the $34.84 million average estimate based on four analysts. The reported number represents a change of -55.3% year over year.
- Sales- Advanced Surgery: $255 million versus the four-analyst average estimate of $260.06 million. The reported number represents a year-over-year change of +3.2%.
View all Key Company Metrics for Baxter here>>>Shares of Baxter have returned -11.3% over the past month versus the Zacks S&P 500 composite's -1.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.